February 24, 2017 08:55 AM EST
Bioregnum
Opinion

Let's not for­get why bio­phar­ma megamerg­ers are such an aw­ful idea

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

A Bris­tol-My­ers Squibb takeover? Not a great idea

This week mur­murs about a pos­si­ble takeover of Bris­tol-My­ers Squibb turned in­to a shout af­ter Carl Ic­ahn re­port­ed­ly stepped up to buy in­to the big biotech. Af­ter a se­ries of painful set­backs on Op­di­vo, BMS has sud­den­ly trad­ed in its white hat for a black one as in­vestors switched al­le­giance to Mer­ck.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
TRENDING NOW

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

FDA gives ac­cel­er­at­ed ap­proval to Day One’s tar­get­ed treat­ment for most com­mon brain tu­mor in kids

Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Why VC leg­end Bob Nelsen is mak­ing the biggest ini­tial bet of his 37-year ca­reer on Xaira

Pas­cal So­ri­ot’s been push­ing for US-sized CEO pay for more than a decade. Now he’s fi­nal­ly get­ting it

Ver­tex li­cens­es TreeFrog’s tech to up­scale cell ther­a­py man­u­fac­tur­ing for di­a­betes can­di­dates

A service from the Financial Times